跳转至内容
Merck
CN

Repurposing CRISPR-Cas13 systems for robust mRNA trans-splicing.

Nature communications (2024-03-15)
David N Fiflis, Nicolas A Rey, Harshitha Venugopal-Lavanya, Beatrice Sewell, Aaron Mitchell-Dick, Katie N Clements, Sydney Milo, Abigail R Benkert, Alan Rosales, Sophia Fergione, Aravind Asokan
摘要

Type VI CRISPR enzymes have been developed as programmable RNA-guided Cas proteins for eukaryotic RNA editing. Notably, Cas13 has been utilized for site-targeted single base edits, demethylation, RNA cleavage or knockdown and alternative splicing. However, the ability to edit large stretches of mRNA transcripts remains a significant challenge. Here, we demonstrate that CRISPR-Cas13 systems can be repurposed to assist trans-splicing of exogenous RNA fragments into an endogenous pre-mRNA transcript, a method termed CRISPR Assisted mRNA Fragment Trans-splicing (CRAFT). Using split reporter-based assays, we evaluate orthogonal Cas13 systems, optimize guide RNA length and screen for optimal trans-splicing site(s) across a range of intronic targets. We achieve markedly improved editing of large 5' and 3' segments in different endogenous mRNAs across various mammalian cell types compared to other spliceosome-mediated trans-splicing methods. CRAFT can serve as a versatile platform for attachment of protein tags, studying the impact of multiple mutations/single nucleotide polymorphisms, modification of untranslated regions (UTRs) or replacing large segments of mRNA transcripts.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
抗 层粘连蛋白-2(α-2 链)抗体,大鼠单克隆, clone 4H8-2, purified from hybridoma cell culture